Background
Molinaroli was born October 7, 1959.
Molinaroli was born October 7, 1959.
He earned a Bachelor of Science in electrical and computer engineering in 1983 from the University of South Carolina. He later earned a Master of Science in business from Northwestern University in Chicago, Illinois.
Molinaroli went to work for Johnson Controls in 1983. He held increasing levels of responsibility for controls systems and services sales and operations, and was Vice President and General Manager for North America Systems and the Middle East for the building efficiency business. Molinaroli championed the development of consistent and effective sales management disciplines within Johnson Controls and has worked to expand that consistent approach on a global basis, involving over 300 sales offices in nearly 50 countries and was promoted to vice president and general manager for the North American Systems business.
Molinaroli was President of Johnson Controls Power Solutions business from January 2007 to January 2013.
In January 2013, Molinaroli was named Vice Chairman of the Johnson Controls. In July 2013, the company announced he would become Chief Executive Officer on October 1, and Chairman of the Board of the company on January 1, 2014.
He replaces Steve Roell in both those positions. Molinaroli, along with the Johnson Controls research lab, has been looking into what the battery-powered future might hold for years.
Johnson Controls has been working on testing the new generation of lithium-ion batteries through electric-vehicle projects from up to 30 years ago.
According to Molinaroli, "Up until now, this has been a science project"
Molinaroli is on the board of directors of the National Center for the Arts and Technology board of directors. He currently resides in Milwaukee, Wisconsin. In October 2014, Joint Commission International elected to terminate a consulting contract with Lichter & Ihle due to an extramarital affair with Kristin Ihle.
He came to the aid of his step-son in 2012 after an arrest involving the manufacture of synthetic drugs.